CD274 and ovarian carcinoma: Immune checkpoint inhibitors (anti-PD-L1 and PD-1) have been FDA approved for melanoma and NSCLC, but only a small percentage (10–33%) of ovarian cancers express PD-L1 [61,92,93], thus only a small percentage of patients may respond to anti-PD-L1 immunotherapy (Table 1).